<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531698</url>
  </required_header>
  <id_info>
    <org_study_id>B1971017</org_study_id>
    <secondary_id>2014-000933-21</secondary_id>
    <secondary_id>6108K2-3012</secondary_id>
    <nct_id>NCT02531698</nct_id>
  </id_info>
  <brief_title>A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged â‰¥24 Months to &lt;10 Years</brief_title>
  <official_title>A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged &gt;/= 24 Months To &lt;10 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at a new vaccine that might prevent meningococcal disease, and will
      study the immune response elicited by this vaccine when given to healthy young children. The
      study will also look at the safety of the new vaccine as well as how it is tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1</measure>
    <time_frame>Within 7 Days after Vaccination 1</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2</measure>
    <time_frame>Within 7 Days after Vaccination 2</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3</measure>
    <time_frame>Within 7 Days after Vaccination 3</time_frame>
    <description>Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1</measure>
    <time_frame>Within 7 Days after Vaccination 1</time_frame>
    <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2</measure>
    <time_frame>Within 7 Days after Vaccination 2</time_frame>
    <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3</measure>
    <time_frame>Within 7 Days after Vaccination 3</time_frame>
    <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1</measure>
    <time_frame>Within 30 Days after Vaccination 1</time_frame>
    <description>SAE was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2</measure>
    <time_frame>Within 30 Days after Vaccination 2</time_frame>
    <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 3</measure>
    <time_frame>Within 30 Days after Vaccination 3</time_frame>
    <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 Days after any vaccination</time_frame>
    <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase</measure>
    <time_frame>From the Vaccination 1 up to 1 month after Vaccination 3</time_frame>
    <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase</measure>
    <time_frame>From 1 month after Vaccination 3 up to 6 months after Vaccination 3</time_frame>
    <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study</measure>
    <time_frame>From Vaccination 1 up to 6 months after Vaccination 3</time_frame>
    <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 1</measure>
    <time_frame>Within 30 Days after Vaccination 1</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 2</measure>
    <time_frame>Within 30 Days after Vaccination 2</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 3</measure>
    <time_frame>Within 30 Days after Vaccination 3</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 Days after any vaccination</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Vaccination Phase</measure>
    <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Follow-up Phase</measure>
    <time_frame>From 1 month after Vaccination 3 up to 6 months after the Vaccination 3</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Throughout the Study</measure>
    <time_frame>From the Vaccination 1 up to 6 months after the Vaccination 3</time_frame>
    <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 1</measure>
    <time_frame>Within 30 Days after Vaccination 1</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 2</measure>
    <time_frame>Within 30 Days after Vaccination 2</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 3</measure>
    <time_frame>Within 30 Days after Vaccination 3</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 Days after any vaccination</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase</measure>
    <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-up Phase</measure>
    <time_frame>From 1 month after Vaccination 3 up to 6 months after the Vaccination 3</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study</measure>
    <time_frame>From the Vaccination 1 up to 6 months after the Vaccination 3</time_frame>
    <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 1</measure>
    <time_frame>Within 30 Days after Vaccination 1</time_frame>
    <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 2</measure>
    <time_frame>Within 30 Days after Vaccination 2</time_frame>
    <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 3</measure>
    <time_frame>Within 30 Days after Vaccination 3</time_frame>
    <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination</measure>
    <time_frame>Within 30 Days after any vaccination</time_frame>
    <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase</measure>
    <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
    <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 1</measure>
    <time_frame>Within 30 minutes after Vaccination 1</time_frame>
    <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 2</measure>
    <time_frame>Within 30 minutes after Vaccination 2</time_frame>
    <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 3</measure>
    <time_frame>Within 30 minutes after Vaccination 3</time_frame>
    <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days Participant's Missed School Due to Adverse Event (AE) During the Vaccination Phase</measure>
    <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Aged &gt;=24 Months to &lt;10 Years With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2 and 6 Months After Vaccination 3</measure>
    <time_frame>1 month after Vaccination 2 and 6 months after Vaccination 3</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Each of the 4 Primary Test Strains</measure>
    <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 1 month after Vaccination 3 and 6 months after Vaccination 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains</measure>
    <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 1 month after Vaccination 3 and 6 months after Vaccination 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>MENINGOCOCCAL INFECTION</condition>
  <arm_group>
    <arm_group_label>Bivalent rLP2086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalent rLP2086 (containing 60 Î¼g each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed pediatric hepatitis A vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent rLP2086 Vaccine</intervention_name>
    <description>1 dose of 120 Î¼g of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.</description>
    <arm_group_label>Bivalent rLP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed pediatric hepatits A vaccine</intervention_name>
    <description>1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.</description>
    <arm_group_label>Licensed pediatric hepatitis A vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.</description>
    <arm_group_label>Licensed pediatric hepatitis A vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document (ICD) indicating
             that the subject's parent(s)/legal guardian has been informed of all pertinent aspects
             of the study.

          2. Parent(s)/legal guardian and subject who are willing and able to comply with scheduled
             visits, vaccine regimen, laboratory tests, and other study procedures.

          3. Male or female subjects aged â‰¥24 months and &lt;10 years at time of randomization,
             stratified equally by age (â‰¥24 months to &lt;4 years or â‰¥4 years to &lt;10 years).

          4. Subject is available for the entire study period and subject's parent(s)/legal
             guardian can be reached by telephone.

          5. Healthy subject as determined by medical history, physical examination, and judgment
             of the investigator.

          6. Subject must have received all vaccinations in the relevant national immunization
             program (NIP) for their age group.

          7. Male and female subjects of childbearing potential and at risk for pregnancy must
             agree to use a highly effective method of contraception throughout the study. A
             subject is of childbearing potential if, in the opinion of the investigator, he/she is
             biologically capable of having children and is sexually active.

          8. Negative urine pregnancy test for all female subjects who are biologically capable of
             having children.

        Exclusion Criteria:

          1. Previous vaccination with any meningococcal serogroup B vaccine.

          2. Subjects who have received prior HAV vaccination.

          3. Contraindication to vaccination with any HAV vaccine or known latex allergy.

          4. Subjects receiving any allergen immunotherapy with a nonlicensed product or subjects
             receiving allergen immunotherapy with a licensed product and who are not on stable
             maintenance doses.

          5. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          6. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          7. A known or suspected defect of the immune system that would prevent an immune response
             to the vaccine, such as subjects with congenital or acquired defects in B-cell
             function, those receiving chronic systemic (oral, intravenous, or intramuscular)
             corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects with
             terminal complement deficiency may be included. Additional details will be provided in
             the study reference manual (SRM).

          8. History of microbiologically proven disease caused by N meningitidis or Neisseria
             gonorrhoeae.

          9. Significant neurological disorder or history of seizure (excluding simple febrile
             seizure).

         10. Receipt of any blood products, including immunoglobulin, within 6 months before the
             first study vaccination.

         11. Current chronic use of systemic antibiotics.

         12. Participation in other studies involving investigational product(s)/device(s) (Phases
             1-4) within 28 days before administration of the first study vaccination.
             Participation in purely observational studies is acceptable.

         13. Any neuroinflammatory or autoimmune condition, including but not limited to transverse
             myelitis, uveitis, optic neuritis, and multiple sclerosis.

         14. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.

         15. Pregnant female subjects, breastfeeding female subjects, male subjects with partners
             who are currently pregnant, or male and female subjects of childbearing potential who
             are unwilling or unable to use a highly effective method of contraception as outlined
             in this protocol for the duration of the study.

         16. Subjects who are children of investigational site staff members directly involved in
             the conduct of the study and their family members, subjects who are children of site
             staff members otherwise supervised by the investigator, or subjects who are children
             of Pfizer employees directly involved in the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Center</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski dr n. med. Jerzy Brzostek</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarza Rodzinnego-Slawin Sp. z o.o.</name>
      <address>
        <city>Kielczow</city>
        <zip>55-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31- 202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanna Czajka - Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Krakow</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Salmed S. C.</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Przychodnia Medycyny Wieku Rozwojowego</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Lecznictwa Ambulatoryjnego &quot;Michalkowice&quot;Jarosz i Partnerzy Spolka Lekarska</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 We Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971017&amp;StudyName=A%20Phase%202%2C%20Randomized%2C%20Controlled%2C%20Observer-blinded%20Study%20To%20Describe%20The%20Immunogenicity%2C%20Safety%2C%20And%20Tolerability%20Of%20Neisseria%20Meningitidis%20Serogroup%20B%20Bivalent%20Recombinant%20Lipoprotein%202086%20Vaccine%20%28bivalent%20Rlp2086%29%20In%20Healthy%20Subjects%20Aged%20greater%20than%2F%3D%2024%20Months%20To%20less%20than10%20Years</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <results_first_submitted>February 28, 2018</results_first_submitted>
  <results_first_submitted_qc>February 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2018</results_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
          <description>Participants from greater than or equal to (&gt;=) 24 months to less than (&lt;) 10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
          <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
          <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
          <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="294"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="2.24"/>
                    <measurement group_id="B2" value="4.2" spread="2.15"/>
                    <measurement group_id="B3" value="4.3" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>1 month after Vaccination 3</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" lower_limit="72.9" upper_limit="91.6"/>
                    <measurement group_id="O2" value="91.0" lower_limit="81.5" upper_limit="96.6"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O4" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O4" value="42.1" lower_limit="20.3" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="74.6" upper_limit="93.3"/>
                    <measurement group_id="O2" value="92.1" lower_limit="82.4" upper_limit="97.4"/>
                    <measurement group_id="O3" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="68.2" upper_limit="88.9"/>
                    <measurement group_id="O2" value="78.3" lower_limit="66.7" upper_limit="87.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
        <time_frame>Within 7 Days after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="60.3" upper_limit="71.4"/>
                    <measurement group_id="O2" value="51.7" lower_limit="43.3" upper_limit="60.1"/>
                    <measurement group_id="O3" value="79.9" lower_limit="72.5" upper_limit="86.0"/>
                    <measurement group_id="O4" value="22.6" lower_limit="15.1" upper_limit="31.8"/>
                    <measurement group_id="O5" value="10.9" lower_limit="4.1" upper_limit="22.2"/>
                    <measurement group_id="O6" value="35.3" lower_limit="22.4" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="27.0" upper_limit="38.0"/>
                    <measurement group_id="O2" value="24.1" lower_limit="17.4" upper_limit="31.9"/>
                    <measurement group_id="O3" value="40.3" lower_limit="32.3" upper_limit="48.6"/>
                    <measurement group_id="O4" value="17.9" lower_limit="11.2" upper_limit="26.6"/>
                    <measurement group_id="O5" value="9.1" lower_limit="3.0" upper_limit="20.0"/>
                    <measurement group_id="O6" value="27.5" lower_limit="15.9" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" lower_limit="25.1" upper_limit="35.9"/>
                    <measurement group_id="O2" value="24.8" lower_limit="18.0" upper_limit="32.7"/>
                    <measurement group_id="O3" value="35.6" lower_limit="27.9" upper_limit="43.8"/>
                    <measurement group_id="O4" value="4.7" lower_limit="1.5" upper_limit="10.7"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.6" upper_limit="6.2"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.8" upper_limit="6.9"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.5" upper_limit="8.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" lower_limit="35.1" upper_limit="46.7"/>
                    <measurement group_id="O2" value="42.1" lower_limit="33.9" upper_limit="50.5"/>
                    <measurement group_id="O3" value="39.6" lower_limit="31.7" upper_limit="47.9"/>
                    <measurement group_id="O4" value="9.4" lower_limit="4.6" upper_limit="16.7"/>
                    <measurement group_id="O5" value="10.9" lower_limit="4.1" upper_limit="22.2"/>
                    <measurement group_id="O6" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="13.5" upper_limit="22.5"/>
                    <measurement group_id="O2" value="22.1" lower_limit="15.6" upper_limit="29.7"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.4" upper_limit="20.0"/>
                    <measurement group_id="O4" value="5.7" lower_limit="2.1" upper_limit="11.9"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.0" upper_limit="17.6"/>
                    <measurement group_id="O6" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="14.4" upper_limit="23.6"/>
                    <measurement group_id="O2" value="18.6" lower_limit="12.6" upper_limit="25.9"/>
                    <measurement group_id="O3" value="18.8" lower_limit="12.9" upper_limit="26.0"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.0" upper_limit="9.4"/>
                    <measurement group_id="O5" value="3.6" lower_limit="0.4" upper_limit="12.5"/>
                    <measurement group_id="O6" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.4" upper_limit="7.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="4.9"/>
                    <measurement group_id="O3" value="7.4" lower_limit="3.7" upper_limit="12.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="26.0" upper_limit="36.9"/>
                    <measurement group_id="O2" value="27.6" lower_limit="20.5" upper_limit="35.6"/>
                    <measurement group_id="O3" value="34.9" lower_limit="27.3" upper_limit="43.1"/>
                    <measurement group_id="O4" value="5.7" lower_limit="2.1" upper_limit="11.9"/>
                    <measurement group_id="O5" value="5.5" lower_limit="1.1" upper_limit="15.1"/>
                    <measurement group_id="O6" value="5.9" lower_limit="1.2" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="8.7" upper_limit="16.5"/>
                    <measurement group_id="O2" value="11.0" lower_limit="6.4" upper_limit="17.3"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.4" upper_limit="20.0"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.0" upper_limit="9.4"/>
                    <measurement group_id="O5" value="3.6" lower_limit="0.4" upper_limit="12.5"/>
                    <measurement group_id="O6" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="13.2" upper_limit="22.2"/>
                    <measurement group_id="O2" value="16.6" lower_limit="10.9" upper_limit="23.6"/>
                    <measurement group_id="O3" value="18.1" lower_limit="12.3" upper_limit="25.3"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.1" upper_limit="7.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
        <time_frame>Within 7 Days after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;number of participants analyzed (N)&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;number of participants analyzed (N)&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="65.2" upper_limit="76.0"/>
                    <measurement group_id="O2" value="63.6" lower_limit="55.2" upper_limit="71.5"/>
                    <measurement group_id="O3" value="77.7" lower_limit="70.1" upper_limit="84.1"/>
                    <measurement group_id="O4" value="12.6" lower_limit="6.9" upper_limit="20.6"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="20.4" lower_limit="10.2" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="34.5" upper_limit="46.1"/>
                    <measurement group_id="O2" value="40.6" lower_limit="32.4" upper_limit="49.1"/>
                    <measurement group_id="O3" value="39.9" lower_limit="31.9" upper_limit="48.2"/>
                    <measurement group_id="O4" value="9.7" lower_limit="4.8" upper_limit="17.1"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="14.3" lower_limit="5.9" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="23.4" upper_limit="34.1"/>
                    <measurement group_id="O2" value="20.3" lower_limit="14.0" upper_limit="27.8"/>
                    <measurement group_id="O3" value="36.5" lower_limit="28.7" upper_limit="44.8"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.8" upper_limit="4.4"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.8" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.2" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="31.5" upper_limit="42.9"/>
                    <measurement group_id="O2" value="36.4" lower_limit="28.5" upper_limit="44.8"/>
                    <measurement group_id="O3" value="37.8" lower_limit="30.0" upper_limit="46.2"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.2" upper_limit="12.2"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.4" upper_limit="21.3"/>
                    <measurement group_id="O2" value="15.4" lower_limit="9.9" upper_limit="22.4"/>
                    <measurement group_id="O3" value="17.6" lower_limit="11.8" upper_limit="24.7"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.2" upper_limit="12.2"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="14.0" upper_limit="23.1"/>
                    <measurement group_id="O2" value="20.3" lower_limit="14.0" upper_limit="27.8"/>
                    <measurement group_id="O3" value="16.2" lower_limit="10.7" upper_limit="23.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="4.1" lower_limit="1.5" upper_limit="8.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="23.4" upper_limit="34.1"/>
                    <measurement group_id="O2" value="27.3" lower_limit="20.2" upper_limit="35.3"/>
                    <measurement group_id="O3" value="29.7" lower_limit="22.5" upper_limit="37.8"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.2" upper_limit="15.9"/>
                    <measurement group_id="O2" value="11.9" lower_limit="7.1" upper_limit="18.4"/>
                    <measurement group_id="O3" value="11.5" lower_limit="6.8" upper_limit="17.8"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="12.1" upper_limit="20.9"/>
                    <measurement group_id="O2" value="14.7" lower_limit="9.3" upper_limit="21.6"/>
                    <measurement group_id="O3" value="17.6" lower_limit="11.8" upper_limit="24.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3</title>
        <description>Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
        <time_frame>Within 7 Days after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3</title>
          <description>Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="62.7" upper_limit="73.8"/>
                    <measurement group_id="O2" value="54.7" lower_limit="46.0" upper_limit="63.1"/>
                    <measurement group_id="O3" value="81.5" lower_limit="74.2" upper_limit="87.4"/>
                    <measurement group_id="O4" value="15.4" lower_limit="9.1" upper_limit="23.8"/>
                    <measurement group_id="O5" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O6" value="22.0" lower_limit="11.5" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="32.6" upper_limit="44.2"/>
                    <measurement group_id="O2" value="26.6" lower_limit="19.5" upper_limit="34.8"/>
                    <measurement group_id="O3" value="49.3" lower_limit="41.0" upper_limit="57.7"/>
                    <measurement group_id="O4" value="10.6" lower_limit="5.4" upper_limit="18.1"/>
                    <measurement group_id="O5" value="7.4" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O6" value="14.0" lower_limit="5.8" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="21.9" upper_limit="32.6"/>
                    <measurement group_id="O2" value="25.2" lower_limit="18.2" upper_limit="33.2"/>
                    <measurement group_id="O3" value="28.8" lower_limit="21.6" upper_limit="36.8"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.9"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="8.0" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.5" upper_limit="5.9"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.8" upper_limit="7.2"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.1" upper_limit="7.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="29.6" upper_limit="40.9"/>
                    <measurement group_id="O2" value="34.5" lower_limit="26.7" upper_limit="43.1"/>
                    <measurement group_id="O3" value="35.6" lower_limit="27.9" upper_limit="44.0"/>
                    <measurement group_id="O4" value="9.6" lower_limit="4.7" upper_limit="17.0"/>
                    <measurement group_id="O5" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O6" value="10.0" lower_limit="3.3" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.4" upper_limit="21.3"/>
                    <measurement group_id="O2" value="15.8" lower_limit="10.2" upper_limit="23.0"/>
                    <measurement group_id="O3" value="17.1" lower_limit="11.4" upper_limit="24.2"/>
                    <measurement group_id="O4" value="8.7" lower_limit="4.0" upper_limit="15.8"/>
                    <measurement group_id="O5" value="7.4" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O6" value="10.0" lower_limit="3.3" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="10.8" upper_limit="19.4"/>
                    <measurement group_id="O2" value="17.3" lower_limit="11.4" upper_limit="24.6"/>
                    <measurement group_id="O3" value="12.3" lower_limit="7.5" upper_limit="18.8"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.9" upper_limit="6.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.1"/>
                    <measurement group_id="O3" value="6.2" lower_limit="2.9" upper_limit="11.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="22.3" upper_limit="32.9"/>
                    <measurement group_id="O2" value="24.5" lower_limit="17.6" upper_limit="32.5"/>
                    <measurement group_id="O3" value="30.1" lower_limit="22.8" upper_limit="38.3"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.9"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="8.4" upper_limit="16.3"/>
                    <measurement group_id="O2" value="9.4" lower_limit="5.1" upper_limit="15.5"/>
                    <measurement group_id="O3" value="14.4" lower_limit="9.1" upper_limit="21.1"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="10.8" upper_limit="19.4"/>
                    <measurement group_id="O2" value="15.1" lower_limit="9.6" upper_limit="22.2"/>
                    <measurement group_id="O3" value="14.4" lower_limit="9.1" upper_limit="21.1"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.2" upper_limit="4.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1</title>
        <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
        <time_frame>Within 7 Days after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1</title>
          <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.3" upper_limit="21.1"/>
                    <measurement group_id="O2" value="21.4" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O3" value="11.4" lower_limit="6.8" upper_limit="17.6"/>
                    <measurement group_id="O4" value="6.6" lower_limit="2.7" upper_limit="13.1"/>
                    <measurement group_id="O5" value="10.9" lower_limit="4.1" upper_limit="22.2"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="3.7" upper_limit="9.5"/>
                    <measurement group_id="O2" value="6.9" lower_limit="3.4" upper_limit="12.3"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.3" upper_limit="10.3"/>
                    <measurement group_id="O4" value="4.7" lower_limit="1.5" upper_limit="10.7"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.0" upper_limit="17.6"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="3.7" upper_limit="9.5"/>
                    <measurement group_id="O2" value="7.6" lower_limit="3.8" upper_limit="13.2"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.9" upper_limit="9.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O5" value="3.6" lower_limit="0.4" upper_limit="12.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to &lt;39.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.1" upper_limit="7.9"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.5 to 40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.8" upper_limit="6.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.1" upper_limit="8.7"/>
                    <measurement group_id="O2" value="9.0" lower_limit="4.9" upper_limit="14.8"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.4" upper_limit="5.8"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.0" upper_limit="9.4"/>
                    <measurement group_id="O5" value="5.5" lower_limit="1.1" upper_limit="15.1"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.4" upper_limit="7.4"/>
                    <measurement group_id="O2" value="7.6" lower_limit="3.8" upper_limit="13.2"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.8"/>
                    <measurement group_id="O4" value="2.8" lower_limit="0.6" upper_limit="8.0"/>
                    <measurement group_id="O5" value="5.5" lower_limit="1.1" upper_limit="15.1"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="4.9"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="6.1" upper_limit="13.1"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.0" upper_limit="18.1"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.3" upper_limit="12.0"/>
                    <measurement group_id="O4" value="6.6" lower_limit="2.7" upper_limit="13.1"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.0" upper_limit="17.6"/>
                    <measurement group_id="O6" value="5.9" lower_limit="1.2" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="4.5" upper_limit="10.7"/>
                    <measurement group_id="O2" value="9.0" lower_limit="4.9" upper_limit="14.8"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.3" upper_limit="10.3"/>
                    <measurement group_id="O4" value="6.6" lower_limit="2.7" upper_limit="13.1"/>
                    <measurement group_id="O5" value="7.3" lower_limit="2.0" upper_limit="17.6"/>
                    <measurement group_id="O6" value="5.9" lower_limit="1.2" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="14.1" upper_limit="23.3"/>
                    <measurement group_id="O2" value="8.3" lower_limit="4.3" upper_limit="14.0"/>
                    <measurement group_id="O3" value="28.2" lower_limit="21.1" upper_limit="36.1"/>
                    <measurement group_id="O4" value="11.3" lower_limit="6.0" upper_limit="18.9"/>
                    <measurement group_id="O5" value="3.6" lower_limit="0.4" upper_limit="12.5"/>
                    <measurement group_id="O6" value="19.6" lower_limit="9.8" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="6.4" upper_limit="13.5"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.1" upper_limit="7.9"/>
                    <measurement group_id="O3" value="15.4" lower_limit="10.0" upper_limit="22.3"/>
                    <measurement group_id="O4" value="6.6" lower_limit="2.7" upper_limit="13.1"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="11.8" lower_limit="4.4" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.6" upper_limit="12.3"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.0" upper_limit="9.7"/>
                    <measurement group_id="O3" value="12.1" lower_limit="7.3" upper_limit="18.4"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.0" upper_limit="9.4"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="5.9" lower_limit="1.2" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="43.1" upper_limit="54.8"/>
                    <measurement group_id="O2" value="55.9" lower_limit="47.4" upper_limit="64.1"/>
                    <measurement group_id="O3" value="42.3" lower_limit="34.2" upper_limit="50.6"/>
                    <measurement group_id="O4" value="25.5" lower_limit="17.5" upper_limit="34.9"/>
                    <measurement group_id="O5" value="20.0" lower_limit="10.4" upper_limit="33.0"/>
                    <measurement group_id="O6" value="31.4" lower_limit="19.1" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" lower_limit="17.2" upper_limit="26.9"/>
                    <measurement group_id="O2" value="24.1" lower_limit="17.4" upper_limit="31.9"/>
                    <measurement group_id="O3" value="19.5" lower_limit="13.4" upper_limit="26.7"/>
                    <measurement group_id="O4" value="14.2" lower_limit="8.1" upper_limit="22.3"/>
                    <measurement group_id="O5" value="9.1" lower_limit="3.0" upper_limit="20.0"/>
                    <measurement group_id="O6" value="19.6" lower_limit="9.8" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="18.7" upper_limit="28.7"/>
                    <measurement group_id="O2" value="27.6" lower_limit="20.5" upper_limit="35.6"/>
                    <measurement group_id="O3" value="19.5" lower_limit="13.4" upper_limit="26.7"/>
                    <measurement group_id="O4" value="8.5" lower_limit="4.0" upper_limit="15.5"/>
                    <measurement group_id="O5" value="5.5" lower_limit="1.1" upper_limit="15.1"/>
                    <measurement group_id="O6" value="11.8" lower_limit="4.4" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.9" upper_limit="6.6"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.5" upper_limit="8.8"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.1" upper_limit="7.7"/>
                    <measurement group_id="O4" value="2.8" lower_limit="0.6" upper_limit="8.0"/>
                    <measurement group_id="O5" value="5.5" lower_limit="1.1" upper_limit="15.1"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain : Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.3" upper_limit="21.1"/>
                    <measurement group_id="O2" value="13.1" lower_limit="8.1" upper_limit="19.7"/>
                    <measurement group_id="O3" value="19.5" lower_limit="13.4" upper_limit="26.7"/>
                    <measurement group_id="O4" value="5.7" lower_limit="2.1" upper_limit="11.9"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="9.8" lower_limit="3.3" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="5.9" upper_limit="12.7"/>
                    <measurement group_id="O2" value="6.2" lower_limit="2.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="11.4" lower_limit="6.8" upper_limit="17.6"/>
                    <measurement group_id="O4" value="4.7" lower_limit="1.5" upper_limit="10.7"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="3.7" upper_limit="9.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.0" upper_limit="9.7"/>
                    <measurement group_id="O3" value="7.4" lower_limit="3.7" upper_limit="12.8"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="3.9" upper_limit="9.9"/>
                    <measurement group_id="O2" value="6.2" lower_limit="2.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.3" upper_limit="12.0"/>
                    <measurement group_id="O4" value="4.7" lower_limit="1.5" upper_limit="10.7"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.6" upper_limit="6.2"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.1" upper_limit="7.9"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.1" upper_limit="7.7"/>
                    <measurement group_id="O4" value="4.7" lower_limit="1.5" upper_limit="10.7"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="7.8" lower_limit="2.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.4" upper_limit="5.7"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.8" upper_limit="6.9"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.1" upper_limit="7.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic Medication Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="31.5" upper_limit="42.9"/>
                    <measurement group_id="O2" value="42.8" lower_limit="34.6" upper_limit="51.2"/>
                    <measurement group_id="O3" value="31.5" lower_limit="24.2" upper_limit="39.7"/>
                    <measurement group_id="O4" value="16.0" lower_limit="9.6" upper_limit="24.4"/>
                    <measurement group_id="O5" value="14.5" lower_limit="6.5" upper_limit="26.7"/>
                    <measurement group_id="O6" value="17.6" lower_limit="8.4" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2</title>
        <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
        <time_frame>Within 7 Days after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2</title>
          <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="8.5" upper_limit="16.3"/>
                    <measurement group_id="O2" value="15.4" lower_limit="9.9" upper_limit="22.4"/>
                    <measurement group_id="O3" value="8.8" lower_limit="4.8" upper_limit="14.6"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.3"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="7.7" lower_limit="3.9" upper_limit="13.3"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.4" upper_limit="10.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.8" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to &lt;39.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.4" upper_limit="5.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.5 to 40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.8" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="2.9" upper_limit="8.4"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.4" upper_limit="10.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.9" upper_limit="9.5"/>
                    <measurement group_id="O4" value="4.9" lower_limit="1.6" upper_limit="11.0"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.7" upper_limit="6.2"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.6" upper_limit="8.9"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.7" upper_limit="6.8"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.4" upper_limit="5.8"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="5.4" upper_limit="12.0"/>
                    <measurement group_id="O2" value="9.8" lower_limit="5.5" upper_limit="15.9"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3.3" upper_limit="12.1"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.2" upper_limit="12.2"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.8" upper_limit="11.2"/>
                    <measurement group_id="O2" value="8.4" lower_limit="4.4" upper_limit="14.2"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3.3" upper_limit="12.1"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.2" upper_limit="12.2"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="14.0" upper_limit="23.1"/>
                    <measurement group_id="O2" value="11.2" lower_limit="6.5" upper_limit="17.5"/>
                    <measurement group_id="O3" value="25.0" lower_limit="18.3" upper_limit="32.8"/>
                    <measurement group_id="O4" value="11.7" lower_limit="6.2" upper_limit="19.5"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="22.4" lower_limit="11.8" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="7.1" upper_limit="14.4"/>
                    <measurement group_id="O2" value="7.7" lower_limit="3.9" upper_limit="13.3"/>
                    <measurement group_id="O3" value="12.8" lower_limit="7.9" upper_limit="19.3"/>
                    <measurement group_id="O4" value="9.7" lower_limit="4.8" upper_limit="17.1"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="18.4" lower_limit="8.8" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.8" upper_limit="11.2"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.1" upper_limit="8.0"/>
                    <measurement group_id="O3" value="11.5" lower_limit="6.8" upper_limit="17.8"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="37.5" upper_limit="49.2"/>
                    <measurement group_id="O2" value="45.5" lower_limit="37.1" upper_limit="54.0"/>
                    <measurement group_id="O3" value="41.2" lower_limit="33.2" upper_limit="49.6"/>
                    <measurement group_id="O4" value="13.6" lower_limit="7.6" upper_limit="21.8"/>
                    <measurement group_id="O5" value="13.0" lower_limit="5.4" upper_limit="24.9"/>
                    <measurement group_id="O6" value="14.3" lower_limit="5.9" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="16.4" upper_limit="26.1"/>
                    <measurement group_id="O2" value="22.4" lower_limit="15.8" upper_limit="30.1"/>
                    <measurement group_id="O3" value="19.6" lower_limit="13.5" upper_limit="26.9"/>
                    <measurement group_id="O4" value="7.8" lower_limit="3.4" upper_limit="14.7"/>
                    <measurement group_id="O5" value="7.4" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O6" value="8.2" lower_limit="2.3" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="15.2" upper_limit="24.6"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.4" upper_limit="27.0"/>
                    <measurement group_id="O3" value="19.6" lower_limit="13.5" upper_limit="26.9"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.2" upper_limit="12.2"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6.1" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.2" upper_limit="5.3"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.1" upper_limit="8.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.4" upper_limit="5.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="9.4" upper_limit="17.5"/>
                    <measurement group_id="O2" value="11.2" lower_limit="6.5" upper_limit="17.5"/>
                    <measurement group_id="O3" value="14.9" lower_limit="9.6" upper_limit="21.6"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="4.1" lower_limit="0.5" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.2" upper_limit="10.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.1" upper_limit="8.0"/>
                    <measurement group_id="O3" value="10.1" lower_limit="5.8" upper_limit="16.2"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="4.1" lower_limit="0.5" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="3.4" upper_limit="9.2"/>
                    <measurement group_id="O2" value="7.0" lower_limit="3.4" upper_limit="12.5"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.9" upper_limit="9.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="4.5" upper_limit="10.8"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.4" upper_limit="10.7"/>
                    <measurement group_id="O3" value="8.8" lower_limit="4.8" upper_limit="14.6"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="8.2" lower_limit="2.3" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.2" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.0"/>
                    <measurement group_id="O3" value="4.1" lower_limit="1.5" upper_limit="8.6"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="8.2" lower_limit="2.3" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.7" upper_limit="6.2"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="6.0"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.9" upper_limit="9.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="6.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic Medication Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="24.7" upper_limit="35.5"/>
                    <measurement group_id="O2" value="32.9" lower_limit="25.2" upper_limit="41.2"/>
                    <measurement group_id="O3" value="27.0" lower_limit="20.1" upper_limit="34.9"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.2" upper_limit="12.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="10.2" lower_limit="3.4" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3</title>
        <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
        <time_frame>Within 7 Days after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3</title>
          <description>Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (&gt;2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (&gt;=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="4.1" upper_limit="10.2"/>
                    <measurement group_id="O2" value="11.5" lower_limit="6.7" upper_limit="18.0"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.1" upper_limit="12.1"/>
                    <measurement group_id="O5" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.7" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.0" upper_limit="10.1"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.2" upper_limit="8.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to &lt;39.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.4" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.5 to 40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.5" upper_limit="5.9"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.6" upper_limit="9.2"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.8" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.8" upper_limit="7.2"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.2" upper_limit="4.9"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="3.8" upper_limit="9.8"/>
                    <measurement group_id="O2" value="6.5" lower_limit="3.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="6.2" lower_limit="2.9" upper_limit="11.4"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.0" upper_limit="8.5"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.5" upper_limit="11.0"/>
                    <measurement group_id="O3" value="4.8" lower_limit="1.9" upper_limit="9.6"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="10.2" upper_limit="18.6"/>
                    <measurement group_id="O2" value="7.2" lower_limit="3.5" upper_limit="12.8"/>
                    <measurement group_id="O3" value="20.5" lower_limit="14.3" upper_limit="28.0"/>
                    <measurement group_id="O4" value="6.7" lower_limit="2.7" upper_limit="13.4"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="12.0" lower_limit="4.5" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.2" upper_limit="14.7"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.5" upper_limit="11.0"/>
                    <measurement group_id="O3" value="15.1" lower_limit="9.7" upper_limit="21.9"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="8.0" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.7" upper_limit="6.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.4" upper_limit="10.5"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="27.9" upper_limit="39.1"/>
                    <measurement group_id="O2" value="36.0" lower_limit="28.0" upper_limit="44.5"/>
                    <measurement group_id="O3" value="30.8" lower_limit="23.5" upper_limit="39.0"/>
                    <measurement group_id="O4" value="17.3" lower_limit="10.6" upper_limit="26.0"/>
                    <measurement group_id="O5" value="18.5" lower_limit="9.3" upper_limit="31.4"/>
                    <measurement group_id="O6" value="16.0" lower_limit="7.2" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="13.9" upper_limit="23.2"/>
                    <measurement group_id="O2" value="16.5" lower_limit="10.8" upper_limit="23.8"/>
                    <measurement group_id="O3" value="19.9" lower_limit="13.7" upper_limit="27.3"/>
                    <measurement group_id="O4" value="11.5" lower_limit="6.1" upper_limit="19.3"/>
                    <measurement group_id="O5" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O6" value="12.0" lower_limit="4.5" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="10.2" upper_limit="18.6"/>
                    <measurement group_id="O2" value="18.0" lower_limit="12.0" upper_limit="25.4"/>
                    <measurement group_id="O3" value="10.3" lower_limit="5.9" upper_limit="16.4"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.1" upper_limit="12.1"/>
                    <measurement group_id="O5" value="7.4" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="8.7" upper_limit="16.7"/>
                    <measurement group_id="O2" value="12.9" lower_limit="7.9" upper_limit="19.7"/>
                    <measurement group_id="O3" value="11.6" lower_limit="6.9" upper_limit="18.0"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.9"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="3.8" upper_limit="9.8"/>
                    <measurement group_id="O2" value="7.2" lower_limit="3.5" upper_limit="12.8"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.4" upper_limit="10.5"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.2" upper_limit="9.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.0" upper_limit="10.1"/>
                    <measurement group_id="O3" value="6.2" lower_limit="2.9" upper_limit="11.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.8"/>
                    <measurement group_id="O5" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.6" upper_limit="11.0"/>
                    <measurement group_id="O2" value="7.2" lower_limit="3.5" upper_limit="12.8"/>
                    <measurement group_id="O3" value="7.5" lower_limit="3.8" upper_limit="13.1"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.9" upper_limit="6.8"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.8" upper_limit="7.2"/>
                    <measurement group_id="O3" value="4.8" lower_limit="1.9" upper_limit="9.6"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.5" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.2" upper_limit="8.2"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.8" upper_limit="6.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic Medication Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="21.3" upper_limit="31.8"/>
                    <measurement group_id="O2" value="25.2" lower_limit="18.2" upper_limit="33.2"/>
                    <measurement group_id="O3" value="27.4" lower_limit="20.3" upper_limit="35.4"/>
                    <measurement group_id="O4" value="10.6" lower_limit="5.4" upper_limit="18.1"/>
                    <measurement group_id="O5" value="13.0" lower_limit="5.4" upper_limit="24.9"/>
                    <measurement group_id="O6" value="8.0" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1</title>
        <description>SAE was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1</title>
          <description>SAE was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2</title>
        <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2</title>
          <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 3</title>
        <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 3</title>
          <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination</title>
        <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after any vaccination</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination</title>
          <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase</title>
        <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>From the Vaccination 1 up to 1 month after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase</title>
          <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase</title>
        <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>From 1 month after Vaccination 3 up to 6 months after Vaccination 3</time_frame>
        <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or HAV/saline) and had safety data available from after post third-vaccination blood draw to 6 months after last study vaccination. Here &quot;N&quot; signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase</title>
          <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or HAV/saline) and had safety data available from after post third-vaccination blood draw to 6 months after last study vaccination. Here &quot;N&quot; signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.7"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study</title>
        <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>From Vaccination 1 up to 6 months after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study</title>
          <description>SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 1</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>Within 30 Days after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 1</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="9.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="18.6" lower_limit="12.6" upper_limit="25.9"/>
                    <measurement group_id="O3" value="8.1" lower_limit="4.2" upper_limit="13.6"/>
                    <measurement group_id="O4" value="13.2" lower_limit="7.4" upper_limit="21.2"/>
                    <measurement group_id="O5" value="16.4" lower_limit="7.8" upper_limit="28.8"/>
                    <measurement group_id="O6" value="9.8" lower_limit="3.3" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 2</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>Within 30 Days after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 2</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="8.5" upper_limit="16.3"/>
                    <measurement group_id="O2" value="10.5" lower_limit="6.0" upper_limit="16.7"/>
                    <measurement group_id="O3" value="13.5" lower_limit="8.5" upper_limit="20.1"/>
                    <measurement group_id="O4" value="11.5" lower_limit="6.1" upper_limit="19.3"/>
                    <measurement group_id="O5" value="14.8" lower_limit="6.6" upper_limit="27.1"/>
                    <measurement group_id="O6" value="8.0" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 3</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>Within 30 Days after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 3</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.2" upper_limit="8.9"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="4.8" lower_limit="1.9" upper_limit="9.6"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.9"/>
                    <measurement group_id="O5" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Any Vaccination</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>Within 30 Days after any vaccination</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Any Vaccination</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="20.9" upper_limit="31.3"/>
                    <measurement group_id="O2" value="29.0" lower_limit="21.7" upper_limit="37.1"/>
                    <measurement group_id="O3" value="22.8" lower_limit="16.3" upper_limit="30.4"/>
                    <measurement group_id="O4" value="26.4" lower_limit="18.3" upper_limit="35.9"/>
                    <measurement group_id="O5" value="30.9" lower_limit="19.1" upper_limit="44.8"/>
                    <measurement group_id="O6" value="21.6" lower_limit="11.3" upper_limit="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Vaccination Phase</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Vaccination Phase</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="37.5" upper_limit="49.1"/>
                    <measurement group_id="O2" value="45.5" lower_limit="37.2" upper_limit="54.0"/>
                    <measurement group_id="O3" value="40.9" lower_limit="33.0" upper_limit="49.3"/>
                    <measurement group_id="O4" value="46.2" lower_limit="36.5" upper_limit="56.2"/>
                    <measurement group_id="O5" value="41.8" lower_limit="28.7" upper_limit="55.9"/>
                    <measurement group_id="O6" value="51.0" lower_limit="36.6" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Follow-up Phase</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>From 1 month after Vaccination 3 up to 6 months after the Vaccination 3</time_frame>
        <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or HAV/saline) and had safety data available from after post third-vaccination blood draw to 6 months after last study vaccination. Here &quot;N&quot; signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Follow-up Phase</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or HAV/saline) and had safety data available from after post third-vaccination blood draw to 6 months after last study vaccination. Here &quot;N&quot; signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="14.0" upper_limit="23.3"/>
                    <measurement group_id="O2" value="20.4" lower_limit="14.0" upper_limit="28.2"/>
                    <measurement group_id="O3" value="16.3" lower_limit="10.7" upper_limit="23.3"/>
                    <measurement group_id="O4" value="12.5" lower_limit="6.8" upper_limit="20.4"/>
                    <measurement group_id="O5" value="13.0" lower_limit="5.4" upper_limit="24.9"/>
                    <measurement group_id="O6" value="12.0" lower_limit="4.5" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Throughout the Study</title>
        <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
        <time_frame>From the Vaccination 1 up to 6 months after the Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Throughout the Study</title>
          <description>A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" lower_limit="42.8" upper_limit="54.5"/>
                    <measurement group_id="O2" value="49.0" lower_limit="40.6" upper_limit="57.4"/>
                    <measurement group_id="O3" value="48.3" lower_limit="40.1" upper_limit="56.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="40.1" upper_limit="59.9"/>
                    <measurement group_id="O5" value="47.3" lower_limit="33.7" upper_limit="61.2"/>
                    <measurement group_id="O6" value="52.9" lower_limit="38.5" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 1</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>Within 30 Days after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 1</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 2</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>Within 30 Days after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 2</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 3</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>Within 30 Days after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 3</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>Within 30 Days after any vaccination</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-up Phase</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>From 1 month after Vaccination 3 up to 6 months after the Vaccination 3</time_frame>
        <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or HAV/saline) and had safety data available from after post third-vaccination blood draw to 6 months after last study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-up Phase</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or HAV/saline) and had safety data available from after post third-vaccination blood draw to 6 months after last study vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study</title>
        <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>From the Vaccination 1 up to 6 months after the Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study</title>
          <description>A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 1</title>
        <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 1</title>
          <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="19.4" upper_limit="29.5"/>
                    <measurement group_id="O2" value="29.0" lower_limit="21.7" upper_limit="37.1"/>
                    <measurement group_id="O3" value="19.5" lower_limit="13.4" upper_limit="26.7"/>
                    <measurement group_id="O4" value="17.9" lower_limit="11.2" upper_limit="26.6"/>
                    <measurement group_id="O5" value="21.8" lower_limit="11.8" upper_limit="35.0"/>
                    <measurement group_id="O6" value="13.7" lower_limit="5.7" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 2</title>
        <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 2</title>
          <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="18.3" upper_limit="28.3"/>
                    <measurement group_id="O2" value="19.6" lower_limit="13.4" upper_limit="27.0"/>
                    <measurement group_id="O3" value="26.4" lower_limit="19.5" upper_limit="34.2"/>
                    <measurement group_id="O4" value="22.1" lower_limit="14.6" upper_limit="31.3"/>
                    <measurement group_id="O5" value="27.8" lower_limit="16.5" upper_limit="41.6"/>
                    <measurement group_id="O6" value="16.0" lower_limit="7.2" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 3</title>
        <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 3</title>
          <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="10.5" upper_limit="18.9"/>
                    <measurement group_id="O2" value="12.9" lower_limit="7.8" upper_limit="19.6"/>
                    <measurement group_id="O3" value="15.6" lower_limit="10.2" upper_limit="22.5"/>
                    <measurement group_id="O4" value="9.6" lower_limit="4.7" upper_limit="17.0"/>
                    <measurement group_id="O5" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O6" value="8.0" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination</title>
        <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 Days after any vaccination</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination</title>
          <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="38.5" upper_limit="50.1"/>
                    <measurement group_id="O2" value="44.8" lower_limit="36.6" upper_limit="53.3"/>
                    <measurement group_id="O3" value="43.6" lower_limit="35.5" upper_limit="52.0"/>
                    <measurement group_id="O4" value="39.6" lower_limit="30.3" upper_limit="49.6"/>
                    <measurement group_id="O5" value="49.1" lower_limit="35.4" upper_limit="62.9"/>
                    <measurement group_id="O6" value="29.4" lower_limit="17.5" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase</title>
        <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase</title>
          <description>AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" lower_limit="56.8" upper_limit="68.1"/>
                    <measurement group_id="O2" value="62.1" lower_limit="53.6" upper_limit="70.0"/>
                    <measurement group_id="O3" value="63.1" lower_limit="54.8" upper_limit="70.8"/>
                    <measurement group_id="O4" value="63.2" lower_limit="53.3" upper_limit="72.4"/>
                    <measurement group_id="O5" value="63.6" lower_limit="49.6" upper_limit="76.2"/>
                    <measurement group_id="O6" value="62.7" lower_limit="48.1" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 1</title>
        <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
        <time_frame>Within 30 minutes after Vaccination 1</time_frame>
        <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 1</title>
          <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
          <population>Vaccination 1 safety population: all participants who received the first dose of investigational products (rLP2086 or HAV vaccine) on Day 1 (Month 0).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 2</title>
        <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
        <time_frame>Within 30 minutes after Vaccination 2</time_frame>
        <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 2</title>
          <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
          <population>Vaccination 2 safety population: all participants who received the second dose of investigational products (rLP2086 or saline) on Month 2 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 3</title>
        <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
        <time_frame>Within 30 minutes after Vaccination 3</time_frame>
        <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 3</title>
          <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
          <population>Vaccination 3 safety population: all participants who received the third dose of investigational product (rLP2086 or HAV vaccine) on Month 6 visit. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Participant's Missed School Due to Adverse Event (AE) During the Vaccination Phase</title>
        <time_frame>From the Vaccination 1 up to 1 month after the Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Participant's Missed School Due to Adverse Event (AE) During the Vaccination Phase</title>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="3.1"/>
                    <measurement group_id="O2" value="7.0" spread="3.7"/>
                    <measurement group_id="O3" value="4.0" spread="2.6"/>
                    <measurement group_id="O4" value="4.6" spread="2.6"/>
                    <measurement group_id="O5" value="7.3" spread="2.3"/>
                    <measurement group_id="O6" value="4.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Aged &gt;=24 Months to &lt;10 Years With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>1 month after Vaccination 3</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Aged &gt;=24 Months to &lt;10 Years With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" lower_limit="80.6" upper_limit="92.5"/>
                    <measurement group_id="O2" value="6.7" lower_limit="1.4" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="20.9" lower_limit="10.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="82.1" upper_limit="93.8"/>
                    <measurement group_id="O2" value="4.3" lower_limit="0.5" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="71.2" upper_limit="85.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2 and 6 Months After Vaccination 3</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
        <time_frame>1 month after Vaccination 2 and 6 months after Vaccination 3</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2 and 6 Months After Vaccination 3</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month after Vaccination 2: PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="60.5" upper_limit="77.0"/>
                    <measurement group_id="O2" value="59.4" lower_limit="46.4" upper_limit="71.5"/>
                    <measurement group_id="O3" value="78.8" lower_limit="67.0" upper_limit="87.9"/>
                    <measurement group_id="O4" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months after Vaccination 3: PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" lower_limit="24.5" upper_limit="41.5"/>
                    <measurement group_id="O2" value="19.0" lower_limit="10.2" upper_limit="30.9"/>
                    <measurement group_id="O3" value="46.0" lower_limit="33.4" upper_limit="59.1"/>
                    <measurement group_id="O4" value="8.5" lower_limit="2.4" upper_limit="20.4"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 2: PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="16.3" lower_limit="6.8" upper_limit="30.7"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O6" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months after Vaccination 3: PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="74.8" upper_limit="88.5"/>
                    <measurement group_id="O2" value="80.3" lower_limit="68.2" upper_limit="89.4"/>
                    <measurement group_id="O3" value="84.3" lower_limit="73.6" upper_limit="91.9"/>
                    <measurement group_id="O4" value="19.6" lower_limit="9.4" upper_limit="33.9"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                    <measurement group_id="O6" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 2: PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" lower_limit="48.0" upper_limit="65.7"/>
                    <measurement group_id="O2" value="49.2" lower_limit="36.6" upper_limit="61.9"/>
                    <measurement group_id="O3" value="65.1" lower_limit="52.0" upper_limit="76.7"/>
                    <measurement group_id="O4" value="8.9" lower_limit="2.5" upper_limit="21.2"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months after Vaccination 3: PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="9.7" upper_limit="22.9"/>
                    <measurement group_id="O2" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O3" value="21.9" lower_limit="12.5" upper_limit="34.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 2: PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" lower_limit="39.6" upper_limit="57.4"/>
                    <measurement group_id="O2" value="57.1" lower_limit="44.0" upper_limit="69.5"/>
                    <measurement group_id="O3" value="40.3" lower_limit="28.5" upper_limit="53.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months after Vaccination 3: PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="5.8" upper_limit="16.8"/>
                    <measurement group_id="O2" value="12.1" lower_limit="5.4" upper_limit="22.5"/>
                    <measurement group_id="O3" value="8.7" lower_limit="3.3" upper_limit="18.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Each of the 4 Primary Test Strains</title>
        <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 1 month after Vaccination 3 and 6 months after Vaccination 3</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Each of the 4 Primary Test Strains</title>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="7.6" upper_limit="19.5"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.6" upper_limit="14.4"/>
                    <measurement group_id="O3" value="19.7" lower_limit="10.9" upper_limit="31.3"/>
                    <measurement group_id="O4" value="6.4" lower_limit="1.3" upper_limit="17.5"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="7.0" upper_limit="18.7"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.6" upper_limit="14.4"/>
                    <measurement group_id="O3" value="18.2" lower_limit="9.8" upper_limit="29.6"/>
                    <measurement group_id="O4" value="6.4" lower_limit="1.3" upper_limit="17.5"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="4.7" upper_limit="15.1"/>
                    <measurement group_id="O2" value="4.4" lower_limit="0.9" upper_limit="12.4"/>
                    <measurement group_id="O3" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O4" value="6.4" lower_limit="1.3" upper_limit="17.5"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.8" upper_limit="7.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="7.9"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.9" upper_limit="12.7"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.1" upper_limit="11.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.1" upper_limit="11.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB80 [A22] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="66.2" upper_limit="81.8"/>
                    <measurement group_id="O2" value="65.6" lower_limit="52.7" upper_limit="77.1"/>
                    <measurement group_id="O3" value="83.3" lower_limit="72.1" upper_limit="91.4"/>
                    <measurement group_id="O4" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB80 [A22] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="63.8" upper_limit="79.8"/>
                    <measurement group_id="O2" value="62.5" lower_limit="49.5" upper_limit="74.3"/>
                    <measurement group_id="O3" value="81.8" lower_limit="70.4" upper_limit="90.2"/>
                    <measurement group_id="O4" value="8.9" lower_limit="2.5" upper_limit="21.2"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB80 [A22] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" lower_limit="33.0" upper_limit="50.5"/>
                    <measurement group_id="O2" value="35.9" lower_limit="24.3" upper_limit="48.9"/>
                    <measurement group_id="O3" value="47.0" lower_limit="34.6" upper_limit="59.7"/>
                    <measurement group_id="O4" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB80 [A22] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="10.9" upper_limit="24.5"/>
                    <measurement group_id="O2" value="14.1" lower_limit="6.6" upper_limit="25.0"/>
                    <measurement group_id="O3" value="19.7" lower_limit="10.9" upper_limit="31.3"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB80 [A22] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="1.7" upper_limit="9.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O3" value="7.6" lower_limit="2.5" upper_limit="16.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 3: PMB80 [A22] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="86.8" upper_limit="96.4"/>
                    <measurement group_id="O2" value="86.8" lower_limit="76.4" upper_limit="93.8"/>
                    <measurement group_id="O3" value="98.5" lower_limit="92.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O5" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O6" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 [A22] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="86.8" upper_limit="96.4"/>
                    <measurement group_id="O2" value="86.8" lower_limit="76.4" upper_limit="93.8"/>
                    <measurement group_id="O3" value="98.5" lower_limit="92.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O5" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O6" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 [A22] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" lower_limit="58.8" upper_limit="75.2"/>
                    <measurement group_id="O2" value="63.2" lower_limit="50.7" upper_limit="74.6"/>
                    <measurement group_id="O3" value="71.6" lower_limit="59.3" upper_limit="82.0"/>
                    <measurement group_id="O4" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                    <measurement group_id="O5" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O6" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 [A22] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="31.0" upper_limit="48.0"/>
                    <measurement group_id="O2" value="38.2" lower_limit="26.7" upper_limit="50.8"/>
                    <measurement group_id="O3" value="40.3" lower_limit="28.5" upper_limit="53.0"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O5" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB80 [A22] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="9.9" upper_limit="22.8"/>
                    <measurement group_id="O2" value="14.7" lower_limit="7.3" upper_limit="25.4"/>
                    <measurement group_id="O3" value="16.4" lower_limit="8.5" upper_limit="27.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB80 [A22] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="31.8" upper_limit="49.6"/>
                    <measurement group_id="O2" value="25.4" lower_limit="15.3" upper_limit="37.9"/>
                    <measurement group_id="O3" value="55.6" lower_limit="42.5" upper_limit="68.1"/>
                    <measurement group_id="O4" value="10.6" lower_limit="3.5" upper_limit="23.1"/>
                    <measurement group_id="O5" value="11.5" lower_limit="2.4" upper_limit="30.2"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB80 [A22] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" lower_limit="30.3" upper_limit="48.0"/>
                    <measurement group_id="O2" value="22.2" lower_limit="12.7" upper_limit="34.5"/>
                    <measurement group_id="O3" value="55.6" lower_limit="42.5" upper_limit="68.1"/>
                    <measurement group_id="O4" value="8.5" lower_limit="2.4" upper_limit="20.4"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB80 [A22] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="13.3" upper_limit="27.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="6.7" upper_limit="25.4"/>
                    <measurement group_id="O3" value="25.4" lower_limit="15.3" upper_limit="37.9"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.1" upper_limit="11.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB80 [A22] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="3.9" upper_limit="14.1"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O3" value="11.1" lower_limit="4.6" upper_limit="21.6"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.1" upper_limit="11.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB80 [A22] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.5" upper_limit="6.8"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 [A56] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="5.9" upper_limit="17.2"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.4" upper_limit="10.4"/>
                    <measurement group_id="O3" value="18.5" lower_limit="9.9" upper_limit="30.0"/>
                    <measurement group_id="O4" value="19.1" lower_limit="9.1" upper_limit="33.3"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                    <measurement group_id="O6" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 [A56] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.2" upper_limit="14.4"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="15.4" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O4" value="14.9" lower_limit="6.2" upper_limit="28.3"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 [A56] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.2" upper_limit="14.4"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="15.4" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O4" value="14.9" lower_limit="6.2" upper_limit="28.3"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 [A56] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="3.2" upper_limit="12.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="13.8" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O4" value="12.8" lower_limit="4.8" upper_limit="25.7"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="17.4" lower_limit="5.0" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 [A56] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.2" upper_limit="8.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O4" value="6.4" lower_limit="1.3" upper_limit="17.5"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="8.7" lower_limit="1.1" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 [A56] -1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="16.3" lower_limit="6.8" upper_limit="30.7"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O6" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.5" lower_limit="92.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="16.3" lower_limit="6.8" upper_limit="30.7"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O6" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="89.5" upper_limit="97.9"/>
                    <measurement group_id="O2" value="97.0" lower_limit="89.5" upper_limit="99.6"/>
                    <measurement group_id="O3" value="92.5" lower_limit="83.4" upper_limit="97.5"/>
                    <measurement group_id="O4" value="11.6" lower_limit="3.9" upper_limit="25.1"/>
                    <measurement group_id="O5" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O6" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="73.5" upper_limit="87.5"/>
                    <measurement group_id="O2" value="80.3" lower_limit="68.7" upper_limit="89.1"/>
                    <measurement group_id="O3" value="82.1" lower_limit="70.8" upper_limit="90.4"/>
                    <measurement group_id="O4" value="7.0" lower_limit="1.5" upper_limit="19.1"/>
                    <measurement group_id="O5" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O6" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="45.3" upper_limit="62.8"/>
                    <measurement group_id="O2" value="62.1" lower_limit="49.3" upper_limit="73.8"/>
                    <measurement group_id="O3" value="46.3" lower_limit="34.0" upper_limit="58.9"/>
                    <measurement group_id="O4" value="2.3" lower_limit="0.1" upper_limit="12.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O6" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 [A56] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="23.3" lower_limit="11.8" upper_limit="38.6"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="47.4" lower_limit="24.4" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 [A56] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="20.9" lower_limit="10.0" upper_limit="36.0"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="42.1" lower_limit="20.3" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 [A56] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="94.9" upper_limit="99.8"/>
                    <measurement group_id="O2" value="97.1" lower_limit="89.8" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="11.6" lower_limit="3.9" upper_limit="25.1"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="21.1" lower_limit="6.1" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 [A56] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="88.1" upper_limit="97.0"/>
                    <measurement group_id="O2" value="92.6" lower_limit="83.7" upper_limit="97.6"/>
                    <measurement group_id="O3" value="94.4" lower_limit="86.2" upper_limit="98.4"/>
                    <measurement group_id="O4" value="4.7" lower_limit="0.6" upper_limit="15.8"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 [A56] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="69.1" upper_limit="83.7"/>
                    <measurement group_id="O2" value="76.5" lower_limit="64.6" upper_limit="85.9"/>
                    <measurement group_id="O3" value="77.5" lower_limit="66.0" upper_limit="86.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2001 [A56] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="76.5" upper_limit="89.8"/>
                    <measurement group_id="O2" value="82.0" lower_limit="70.0" upper_limit="90.6"/>
                    <measurement group_id="O3" value="85.7" lower_limit="75.3" upper_limit="92.9"/>
                    <measurement group_id="O4" value="21.7" lower_limit="10.9" upper_limit="36.4"/>
                    <measurement group_id="O5" value="20.8" lower_limit="7.1" upper_limit="42.2"/>
                    <measurement group_id="O6" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2001 [A56] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" lower_limit="72.3" upper_limit="86.6"/>
                    <measurement group_id="O2" value="77.0" lower_limit="64.5" upper_limit="86.8"/>
                    <measurement group_id="O3" value="82.9" lower_limit="72.0" upper_limit="90.8"/>
                    <measurement group_id="O4" value="19.6" lower_limit="9.4" upper_limit="33.9"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                    <measurement group_id="O6" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2001 [A56] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" lower_limit="56.9" upper_limit="73.7"/>
                    <measurement group_id="O2" value="59.0" lower_limit="45.7" upper_limit="71.4"/>
                    <measurement group_id="O3" value="71.4" lower_limit="59.4" upper_limit="81.6"/>
                    <measurement group_id="O4" value="13.0" lower_limit="4.9" upper_limit="26.3"/>
                    <measurement group_id="O5" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                    <measurement group_id="O6" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2001 [A56] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" lower_limit="35.6" upper_limit="53.2"/>
                    <measurement group_id="O2" value="39.3" lower_limit="27.1" upper_limit="52.7"/>
                    <measurement group_id="O3" value="48.6" lower_limit="36.4" upper_limit="60.8"/>
                    <measurement group_id="O4" value="6.5" lower_limit="1.4" upper_limit="17.9"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2001 [A56] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="12.7" upper_limit="26.9"/>
                    <measurement group_id="O2" value="16.4" lower_limit="8.2" upper_limit="28.1"/>
                    <measurement group_id="O3" value="21.4" lower_limit="12.5" upper_limit="32.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 [B24] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="3.1" upper_limit="12.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.9" upper_limit="12.5"/>
                    <measurement group_id="O3" value="9.0" lower_limit="3.4" upper_limit="18.5"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.5"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 [B24] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="2.1" upper_limit="10.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.4" upper_limit="10.4"/>
                    <measurement group_id="O3" value="7.5" lower_limit="2.5" upper_limit="16.6"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.5"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 [B24] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="1.7" upper_limit="9.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.4" upper_limit="10.4"/>
                    <measurement group_id="O3" value="6.0" lower_limit="1.7" upper_limit="14.6"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.3"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 [B24] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.8" upper_limit="7.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.9" upper_limit="12.5"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.3"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 [B24] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.2" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 [B24] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 [B24] - 1:4 (n=128,65,63,45,24,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="51.9" upper_limit="69.4"/>
                    <measurement group_id="O2" value="53.8" lower_limit="41.0" upper_limit="66.3"/>
                    <measurement group_id="O3" value="68.3" lower_limit="55.3" upper_limit="79.4"/>
                    <measurement group_id="O4" value="8.9" lower_limit="2.5" upper_limit="21.2"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.1" upper_limit="27.0"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 [B24] - 1:16 (n=128,65,63,45,24,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="41.8" upper_limit="59.7"/>
                    <measurement group_id="O2" value="43.1" lower_limit="30.8" upper_limit="56.0"/>
                    <measurement group_id="O3" value="58.7" lower_limit="45.6" upper_limit="71.0"/>
                    <measurement group_id="O4" value="8.9" lower_limit="2.5" upper_limit="21.2"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O6" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 [B24] - 1:32 (n=128,65,63,45,24,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="15.7" upper_limit="30.9"/>
                    <measurement group_id="O2" value="15.4" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O3" value="30.2" lower_limit="19.2" upper_limit="43.0"/>
                    <measurement group_id="O4" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 [B24] - 1:64 (n=128,65,63,45,24,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="4.9" upper_limit="15.8"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O3" value="15.9" lower_limit="7.9" upper_limit="27.3"/>
                    <measurement group_id="O4" value="4.4" lower_limit="0.5" upper_limit="15.1"/>
                    <measurement group_id="O5" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 [B24] - 1:128 (n=128,65,63,45,24,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="1.7" upper_limit="9.9"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O3" value="7.9" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 [B24] - 1:4 (n=126,63,63,46,26,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="86.9" upper_limit="96.7"/>
                    <measurement group_id="O2" value="90.5" lower_limit="80.4" upper_limit="96.4"/>
                    <measurement group_id="O3" value="95.2" lower_limit="86.7" upper_limit="99.0"/>
                    <measurement group_id="O4" value="6.5" lower_limit="1.4" upper_limit="17.9"/>
                    <measurement group_id="O5" value="11.5" lower_limit="2.4" upper_limit="30.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 [B24] - 1:16 (n=126,63,63,46,26,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="77.5" upper_limit="90.7"/>
                    <measurement group_id="O2" value="81.0" lower_limit="69.1" upper_limit="89.8"/>
                    <measurement group_id="O3" value="88.9" lower_limit="78.4" upper_limit="95.4"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.8"/>
                    <measurement group_id="O5" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 [B24] - 1:32 (n=126,63,63,46,26,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" lower_limit="37.9" upper_limit="55.9"/>
                    <measurement group_id="O2" value="38.1" lower_limit="26.1" upper_limit="51.2"/>
                    <measurement group_id="O3" value="55.6" lower_limit="42.5" upper_limit="68.1"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 [B24] - 1:64 (n=126,63,63,46,26,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="11.9" upper_limit="26.1"/>
                    <measurement group_id="O2" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                    <measurement group_id="O3" value="27.0" lower_limit="16.6" upper_limit="39.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 [B24] - 1:128 (n=126,63,63,46,26,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="3.3" upper_limit="13.1"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O3" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2948 [B24] - 1:4 (n=129,65,64,47,26,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="13.6" upper_limit="28.1"/>
                    <measurement group_id="O2" value="13.8" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O3" value="26.6" lower_limit="16.3" upper_limit="39.1"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.1" upper_limit="11.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2948 [B24] - 1:16 (n=129,65,64,47,26,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="9.1" upper_limit="22.0"/>
                    <measurement group_id="O2" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O3" value="20.3" lower_limit="11.3" upper_limit="32.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2948 [B24] - 1:32 (n=129,65,64,47,26,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="4.9" upper_limit="15.7"/>
                    <measurement group_id="O2" value="6.2" lower_limit="1.7" upper_limit="15.0"/>
                    <measurement group_id="O3" value="12.5" lower_limit="5.6" upper_limit="23.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2948 [B24] - 1:64 (n=129,65,64,47,26,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="1.7" upper_limit="9.8"/>
                    <measurement group_id="O2" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.0" upper_limit="13.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2948 [B24] - 1:128 (n=129,65,64,47,26,21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0.9" upper_limit="7.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44] - 1:4 (n=138,67,71,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.0" upper_limit="7.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44] - 1:8 (n=138,67,71,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44] - 1:16 (n=138,67,71,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44] - 1:32 (n=138,67,71,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44] - 1:64 (n=138,67,71,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44] - 1:128 (n=138,67,71,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 [B44] - 1:4 (n=130,63,67,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="48.7" upper_limit="63.3"/>
                    <measurement group_id="O2" value="66.7" lower_limit="53.7" upper_limit="78.0"/>
                    <measurement group_id="O3" value="49.3" lower_limit="36.8" upper_limit="61.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 [B44] - 1:16 (n=130,63,67,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="34.4" upper_limit="52.0"/>
                    <measurement group_id="O2" value="55.6" lower_limit="42.5" upper_limit="68.1"/>
                    <measurement group_id="O3" value="31.3" lower_limit="20.6" upper_limit="43.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 [B44] - 1:32 (n=130,63,67,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="22.3" upper_limit="38.7"/>
                    <measurement group_id="O2" value="46.0" lower_limit="33.4" upper_limit="59.1"/>
                    <measurement group_id="O3" value="14.9" lower_limit="7.4" upper_limit="25.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 [B44] - 1:64(n=130,63,67,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="11.6" upper_limit="25.4"/>
                    <measurement group_id="O2" value="27.0" lower_limit="16.6" upper_limit="39.7"/>
                    <measurement group_id="O3" value="9.0" lower_limit="3.4" upper_limit="18.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 [B44] - 1:128 (n=130,63,67,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.4" upper_limit="16.5"/>
                    <measurement group_id="O2" value="15.9" lower_limit="7.9" upper_limit="27.3"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.9" upper_limit="12.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 [B44] - 1:4 (n=134,65,69,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" lower_limit="74.5" upper_limit="88.2"/>
                    <measurement group_id="O2" value="81.5" lower_limit="70.0" upper_limit="90.1"/>
                    <measurement group_id="O3" value="82.6" lower_limit="71.6" upper_limit="90.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 [B44] - 1:16 (n=134,65,69,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="69.6" upper_limit="84.4"/>
                    <measurement group_id="O2" value="80.0" lower_limit="68.2" upper_limit="88.9"/>
                    <measurement group_id="O3" value="75.4" lower_limit="63.5" upper_limit="84.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 [B44] - 1:32 (n=134,65,69,50,26,24))</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" lower_limit="57.0" upper_limit="73.7"/>
                    <measurement group_id="O2" value="67.7" lower_limit="54.9" upper_limit="78.8"/>
                    <measurement group_id="O3" value="63.8" lower_limit="51.3" upper_limit="75.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 [B44] - 1:64 (n=134,65,69,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="43.4" upper_limit="60.9"/>
                    <measurement group_id="O2" value="55.4" lower_limit="42.5" upper_limit="67.7"/>
                    <measurement group_id="O3" value="49.3" lower_limit="37.0" upper_limit="61.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 [B44] - 1:128 (n=134,65,69,50,26,24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="25.7" upper_limit="42.2"/>
                    <measurement group_id="O2" value="36.9" lower_limit="25.3" upper_limit="49.8"/>
                    <measurement group_id="O3" value="30.4" lower_limit="19.9" upper_limit="42.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2707 [B44] - 1:4 (n=135,66,69,49,26,23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="8.1" upper_limit="20.3"/>
                    <measurement group_id="O2" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O3" value="13.0" lower_limit="6.1" upper_limit="23.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2707 [B44] - 1:16 (n=135,66,69,49,26,23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="4.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="9.1" lower_limit="3.4" upper_limit="18.7"/>
                    <measurement group_id="O3" value="7.2" lower_limit="2.4" upper_limit="16.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2707 [B44] - 1:32 (n=135,66,69,49,26,23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="3.1" upper_limit="12.3"/>
                    <measurement group_id="O2" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O3" value="7.2" lower_limit="2.4" upper_limit="16.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2707 [B44] - 1:64 (n=135,66,69,49,26,23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="2.1" upper_limit="10.4"/>
                    <measurement group_id="O2" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O3" value="4.3" lower_limit="0.9" upper_limit="12.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2707 [B44] - 1:128 (n=135,66,69,49,26,23)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.8" upper_limit="7.4"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.4" upper_limit="10.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains</title>
        <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 1 month after Vaccination 3 and 6 months after Vaccination 3</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Bivalent rLP2086 (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
            <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;4 Years)</title>
            <description>Participants from &gt;=24 months to &lt;4 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2 HAV/Saline (&gt;=4 Years to &lt;10 Years)</title>
            <description>Participants from &gt;=4 years to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains</title>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="8.3" upper_limit="9.1"/>
                    <measurement group_id="O2" value="8.3" lower_limit="7.9" upper_limit="8.8"/>
                    <measurement group_id="O3" value="9.1" lower_limit="8.3" upper_limit="9.9"/>
                    <measurement group_id="O4" value="8.9" lower_limit="7.8" upper_limit="10.1"/>
                    <measurement group_id="O5" value="8.2" lower_limit="7.8" upper_limit="8.7"/>
                    <measurement group_id="O6" value="9.8" lower_limit="7.2" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="17.4" upper_limit="23.2"/>
                    <measurement group_id="O2" value="17.4" lower_limit="14.2" upper_limit="21.4"/>
                    <measurement group_id="O3" value="23.1" lower_limit="18.9" upper_limit="28.3"/>
                    <measurement group_id="O4" value="8.6" lower_limit="7.7" upper_limit="9.7"/>
                    <measurement group_id="O5" value="8.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="9.4" lower_limit="7.4" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 3: PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" lower_limit="30.5" upper_limit="42.2"/>
                    <measurement group_id="O2" value="33.7" lower_limit="26.4" upper_limit="42.9"/>
                    <measurement group_id="O3" value="38.2" lower_limit="30.6" upper_limit="47.6"/>
                    <measurement group_id="O4" value="8.8" lower_limit="7.8" upper_limit="9.8"/>
                    <measurement group_id="O5" value="8.7" lower_limit="7.3" upper_limit="10.3"/>
                    <measurement group_id="O6" value="8.9" lower_limit="7.6" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after Vaccination 3: PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="10.9" upper_limit="14.2"/>
                    <measurement group_id="O2" value="10.9" lower_limit="9.0" upper_limit="13.1"/>
                    <measurement group_id="O3" value="14.2" lower_limit="11.8" upper_limit="17.0"/>
                    <measurement group_id="O4" value="8.7" lower_limit="7.9" upper_limit="9.7"/>
                    <measurement group_id="O5" value="8.4" lower_limit="7.8" upper_limit="9.1"/>
                    <measurement group_id="O6" value="9.1" lower_limit="7.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.3" upper_limit="5.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.9" upper_limit="4.3"/>
                    <measurement group_id="O3" value="5.8" lower_limit="4.6" upper_limit="7.3"/>
                    <measurement group_id="O4" value="5.6" lower_limit="4.4" upper_limit="7.2"/>
                    <measurement group_id="O5" value="4.9" lower_limit="3.7" upper_limit="6.6"/>
                    <measurement group_id="O6" value="6.5" lower_limit="4.3" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="83.0" upper_limit="112.5"/>
                    <measurement group_id="O2" value="103.8" lower_limit="84.2" upper_limit="127.9"/>
                    <measurement group_id="O3" value="90.0" lower_limit="71.9" upper_limit="112.7"/>
                    <measurement group_id="O4" value="5.8" lower_limit="4.4" upper_limit="7.6"/>
                    <measurement group_id="O5" value="5.0" lower_limit="3.6" upper_limit="7.1"/>
                    <measurement group_id="O6" value="6.6" lower_limit="4.2" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 3: PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.3" lower_limit="156.7" upper_limit="214.4"/>
                    <measurement group_id="O2" value="175.6" lower_limit="139.1" upper_limit="221.6"/>
                    <measurement group_id="O3" value="191.0" lower_limit="153.9" upper_limit="237.1"/>
                    <measurement group_id="O4" value="6.0" lower_limit="4.6" upper_limit="7.7"/>
                    <measurement group_id="O5" value="4.5" lower_limit="3.5" upper_limit="5.7"/>
                    <measurement group_id="O6" value="8.6" lower_limit="5.4" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after Vaccination 3: PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="25.3" upper_limit="38.7"/>
                    <measurement group_id="O2" value="27.0" lower_limit="19.7" upper_limit="36.9"/>
                    <measurement group_id="O3" value="35.7" lower_limit="26.6" upper_limit="47.8"/>
                    <measurement group_id="O4" value="6.0" lower_limit="4.6" upper_limit="7.8"/>
                    <measurement group_id="O5" value="6.0" lower_limit="4.0" upper_limit="8.9"/>
                    <measurement group_id="O6" value="6.0" lower_limit="4.2" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.1" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.8" upper_limit="4.9"/>
                    <measurement group_id="O3" value="4.6" lower_limit="4.0" upper_limit="5.2"/>
                    <measurement group_id="O4" value="4.4" lower_limit="3.9" upper_limit="4.9"/>
                    <measurement group_id="O5" value="4.3" lower_limit="3.7" upper_limit="5.1"/>
                    <measurement group_id="O6" value="4.4" lower_limit="3.6" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vaccination 2: PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="9.2" upper_limit="13.5"/>
                    <measurement group_id="O2" value="9.1" lower_limit="7.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="13.7" lower_limit="10.3" upper_limit="18.2"/>
                    <measurement group_id="O4" value="4.8" lower_limit="4.0" upper_limit="5.8"/>
                    <measurement group_id="O5" value="4.8" lower_limit="3.7" upper_limit="6.2"/>
                    <measurement group_id="O6" value="4.9" lower_limit="3.6" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="19.1" upper_limit="26.8"/>
                    <measurement group_id="O2" value="19.1" lower_limit="14.9" upper_limit="24.5"/>
                    <measurement group_id="O3" value="26.8" lower_limit="21.3" upper_limit="33.9"/>
                    <measurement group_id="O4" value="4.3" lower_limit="3.9" upper_limit="4.8"/>
                    <measurement group_id="O5" value="4.6" lower_limit="3.8" upper_limit="5.6"/>
                    <measurement group_id="O6" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="4.8" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.1" upper_limit="6.3"/>
                    <measurement group_id="O3" value="6.2" lower_limit="4.9" upper_limit="7.7"/>
                    <measurement group_id="O4" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O5" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O2" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O3" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O4" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O5" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="9.3" upper_limit="14.7"/>
                    <measurement group_id="O2" value="17.1" lower_limit="11.8" upper_limit="24.8"/>
                    <measurement group_id="O3" value="8.2" lower_limit="6.3" upper_limit="10.6"/>
                    <measurement group_id="O4" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O5" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="30.6" upper_limit="51.6"/>
                    <measurement group_id="O2" value="43.6" lower_limit="29.9" upper_limit="63.6"/>
                    <measurement group_id="O3" value="36.5" lower_limit="25.2" upper_limit="52.7"/>
                    <measurement group_id="O4" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O5" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.4" upper_limit="5.9"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.2" upper_limit="6.4"/>
                    <measurement group_id="O3" value="5.0" lower_limit="4.1" upper_limit="6.2"/>
                    <measurement group_id="O4" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O5" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs: Recorded from first vaccination through 6 months after third vaccination. Participants recorded local reactions and systemic events in e-diary within 7 days after first, second and third vaccination.</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and preferred term. AEs included AEs collected in the e-diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Bivalent rLP2086 (&gt;=24 Months to &lt;10 Years)</title>
          <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 HAV/Saline (&gt;=24 Months to &lt;10 Years)</title>
          <description>Participants from &gt;=24 months to &lt;10 years of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diarrhoea (diarrhea)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Injection site erythema (redness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Injection site hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Injection site pain (pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Injection site swelling (swelling)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pyrexia (fever)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Foot and mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Herpes dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Otitis media viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <description>This event is a gender specific event.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Nasal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <description>This event is a gender specific event.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

